Trial · NCT02808819
Outcomes17
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Basophils, Full Analysis Set | From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented. | Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value. | 10^9 cells/L | MEAN |
| PRIMARY | Change From Baseline in Leukocytes, Full Analysis Set | From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented. | Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value. | 10^9 cells/L | MEAN |
| PRIMARY | Change From Baseline in Lymphocytes, Full Analysis Set | From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented. | Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value. | 10^9 cells/L | MEAN |
| PRIMARY | Change From Baseline in Neutrophils, Full Analysis Set | From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented. | Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value. | 10^9 cells/L | MEAN |
| PRIMARY | Change From Baseline in Monocytes, Full Analysis Set | From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented. | Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value. | 10^9 cells/L | MEAN |
| PRIMARY | Change From Baseline in Platelets, Full Analysis Set | From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented. | Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value. | 10^9 cells/L | MEAN |
| PRIMARY | Change From Baseline in Hematocrit, Full Analysis Set | From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented. | Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value. | [ratio] | MEAN |
| PRIMARY | Change From Baseline in Erythrocytes, Full Analysis Set | From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented. | Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value. | 10^12 cells/L | MEAN |
| PRIMARY | Change From Baseline in Hemoglobin, Full Analysis Set | From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented. | Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value. | g/L | MEAN |
| PRIMARY | Change From Baseline in Alanine Aminotransferase (ALT), Full Analysis Set | From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented. | Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value. | ukat/L | MEAN |
| PRIMARY | Change From Baseline in Aspartate Aminotransferase (AST), Full Analysis Set | From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented. | Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value. | ukat/L | MEAN |
| PRIMARY | Change From Baseline in Bilirubin, Full Analysis Set | From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented. | Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value. | umol/L | MEAN |
| SECONDARY | Number of Participants With Asthma Exacerbations During Study Period | From week 0 to week 184 in study treatment period and through the follow up period (12 weeks from day of last dose). Number and percentage of participants with asthma exacerbation during this period is presented. | Full analysis set. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Who Had Health Care Encounter (ie, Hospitalization, Emergency Department Visits, Urgent Care Visits, and All Other Outpatient Visits Due to Asthma) During Study Period | From week 0 to week 184 in study treatment period and through the follow up period (12 weeks from day of last dose). Number and percentage of participants with health care encounters during this period is presented. | Full analysis set. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Change of Blood Eosinophils Count | From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented. | Full analysis set. | cell/uL | MEAN |
| SECONDARY | Number of Participants With Anti-drug Antibodies (ADA) Responses During the Study | From week 0 to week 184 in study treatment period and plus 12 weeks follow up period | Full analysis set. | Participants | NUMBER |
| SECONDARY | Duration of Exposure | From week 0 to week 184 in study treatment period | Full analysis set. | months | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02808819/outcomes